Efficacy and safety of administration of vonoprazan after endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma

Efficacy and safety of administration of vonoprazan after endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma - Efficacy of vonoprazan after ESD for gastric neoplasms

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018169

Enrollment

Registered

2015-07-02

Start date

2015-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric adenoma/carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma

Exclusion criteria

Exclusion criteria: Patients evaluated incompetent by doctors in attendance

Design outcomes

Primary

Measure	Time frame
The rate of the stage of scar at 4 weeks after endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma (comparison of vonoprazan and esomeprazole as historical control group)	—

Secondary

Measure	Time frame
The diameter of the ulcer at 4 weeks after endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma and relationship between these and patients background or lesion information (comparison of vonoprazan and esomeprazole as historical control group)	—

Countries

Japan

Contacts

Public ContactDaisuke Maruoka

Chiba University Hospital Gastroenterology

maruoka-cib@umin.ac.jp043-226-2083

Outcome results